Navigation Links
Certain Bone Drugs May Lower Breast Cancer Risk
Date:3/5/2010

Benefit from Fosamax, Boniva, Zometa does not apply to obese women, however

FRIDAY, March 5 (HealthDay News) -- Some types of bone-building drugs used to prevent and treat osteoporosis might reduce the risk of breast cancer, according to new research.

The study, which included 6,000 Wisconsin women aged 20 to 69, found that those who took bisphosphonate drugs such as Fosamax, Boniva and Zometa for more than two years were 40 percent less likely to develop breast cancer than were women who did not take the drugs.

However, the protective effective was seen only among women who were not obese.

"Obese women may have elevated estrogen levels, so underlying hormones may influence the ability of bisphosphonates to reduce breast cancer risk," the study's lead author, Polly Newcomb, head of the cancer prevention program at Fred Hutchinson Cancer Research Center in Seattle, said in a news release from the center.

The study is published online and in the March print issue of the British Journal of Cancer.

Just how bisphosphonate drugs affect the risk for breast cancer is unclear, but there are a number of possibilities.

"These drugs may affect cell function and be important in cell growth and death -- specifically the death of tumors or even premalignant disease," Newcomb said.

Also, previous studies have found that some kinds of bisphosphonates trigger tumor cell death, prevent tumors from establishing a blood supply and prevent cancer cells from binding to each other.

More information

The U.S. National Cancer Institute has more about breast cancer prevention.



-- Robert Preidt



SOURCE: Fred Hutchinson Cancer Research Center, news release, March 2, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
3. MU researchers studying model to learn why certain cancers become resistant to drugs
4. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
5. Effectiveness of most PTSD therapies is uncertain
6. Value of Most Post-Traumatic Stress Treatments Uncertain
7. Certain Seizure Patients Need Emergency CT Scan
8. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
9. Certain Cholesterol Drugs Show Their Limits
10. ADHD Delays Growth of Certain Brain Areas
11. Stress hormone may hasten the progression of certain blood cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall ... who live with dental fear and require sedation to receive dental care. The doctors ... during various procedures, from hygienic cleanings to oral surgery, at their dental office in ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Back ... neck and back pain with a reputable physician in their area, announces the launch ... protects patient information for patients who are looking for reputable physicians to help them ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South ... special report in the May issue of Consumer Reports focused on heart health. ... results achieved during and after coronary bypass and aortic valve replacement procedures. , ...
(Date:4/24/2017)... ... , ... Michael Vick announced his retirement earlier this year from the NFL ... one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro ... career rushing yards by a quarterback (6,109) and the most rushing yards by a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: